Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
found
Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.
You are not logged in so some information on this page has been withheld. To see more, please log in.
Nordisk
since
auto-detected in 51 stories
5 days ago
17 days ago
Novo Nordisk says WeightWatchers will sell Wegovy, announces $299 price
found
Under the deal, cash-paying patients can access a month's supply of Wegovy through the Danish drugmaker's Novocare pharmacy for $299.
21 days ago
Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%
Novo Nordisk said Hims & Hers has "failed to adhere to the law which prohibits mass sales of compounded drugs" under the "false guise" of personalization.
32 days ago
Healthy Returns: Ozempic, Wegovy linked to rare cases of serious eye condition
Novo Nordisk's drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC's Disruptor 50 List.
55 days ago
Novo Nordisk's future in doubt after Wegovy maker's 'surprise' CEO ouster
Novo Nordisk's ousting of longtime CEO Lars Fruergaard Jørgensen bemused analysts, with many questioning the future of the Wegovy obesity drug maker.
Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and navigate other challenges
59 days ago
Novo Nordisk CEO to step down as Wegovy maker faces growing competition
found
The Danish pharmaceutical giant said Fruergaard Jørgensen would remain in his post "for a period to support a smooth transition to new leadership."
Novo Nordisk chief Jørgensen to step down
Danish maker of obesity drugs says that new leadership is needed
68 days ago
Novo Nordisk cuts forecasts after replica obesity drugs hit US take-up
‘Compounded’ drugs custom made by pharmacies appeared after US regulator declared shortages in 2022
Novo Nordisk cuts 2025 guidance as drug copycats hit Wegovy sales, posts first-quarter profit beat
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.